| Richard C. Mohs | |
|---|---|
| Photo placeholder | |
| Affiliations | NIH NIA |
| Country | USA |
| H-index | 80 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Clinical trials, Biomarkers |
Richard C. Mohs is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mohs has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at NIH and NIA, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.
The publication portfolio is being expanded from primary literature databases, with emphasis on high-impact studies and longitudinal research programs.
Their program contributes to translational and mechanistic work in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
The lab emphasizes Clinical trials to connect molecular findings with patient outcomes. The lab emphasizes [Biomarkers] to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.
Current priorities in Mohs's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response. A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.
Collaborator network pending enrichment.
[Rogers SL et al.. "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's Disease. [Donepezil[/entities/[donepezil[/entities/[donepezil[/entities/[donepezil--TEMP--/entities)--FIX-- Study Group." Neurology (1998). DOI)
[Afshar S et al.. "Plasma proteomic associations with Alzheimer's Disease endophenotypes." Nature aging (2025). DOI)
[Aisen P et al.. "The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's Disease based on clearcut biomarker evidence." Alzheimers Dement (2025). DOI)
[Doody RS et al.. "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's Disease." The New England journal of medicine (2014). DOI)
[Fillenbaum GG, Mohs R. "CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting." Journal of Alzheimer's Disease : JAD (2023). DOI)
[Näslund J et al.. "Correlation between elevated levels of [Amyloid-Beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---peptide in the brain and cognitive decline." JAMA (2000). DOI)
[Khachaturian AS et al.. "Future prospects and challenges for Alzheimer's Disease drug development in the era of the NIA-AA Research Framework." Alzheimers Dement (2018). DOI)
[Khachaturian AS et al.. "New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia." Alzheimers Dement (2018). DOI)
[Rogers SL et al.. "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's Disease. Donepezil Study Group." Neurology (1998). [DOI: 10.1212/wnl.50.1.136]https://doi.org/10.1212/wnl.50.1.136) PubMed: 9443470
[Afshar S et al.. "Plasma proteomic associations with Alzheimer's Disease endophenotypes." Nature aging (2025). [DOI: 10.1038/s43587-025-00965-4]https://doi.org/10.1038/s43587-025-00965-4) PubMed: 40931114
[Aisen P et al.. "The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's Disease based on clearcut biomarker evidence." Alzheimers Dement (2025). [DOI: 10.1002/alz.14342]https://doi.org/10.1002/alz.14342) PubMed: 39535341
[Doody RS et al.. "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's Disease." The New England journal of medicine (2014). [DOI: 10.1056/NEJMoa1312889]https://doi.org/10.1056/NEJMoa1312889) PubMed: 24450890
[Fillenbaum GG, Mohs R. "CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting." Journal of Alzheimer's Disease : JAD (2023). [DOI: 10.3233/JAD-230026]https://doi.org/10.3233/JAD-230026) PubMed: 36938738
[Näslund J et al.. "Correlation between elevated levels of Amyloid-Beta-peptide in the brain and cognitive decline." JAMA (2000). [DOI: 10.1001/jama.283.12.1571]https://doi.org/10.1001/jama.283.12.1571) PubMed: 10735393
[Khachaturian AS et al.. "Future prospects and challenges for Alzheimer's Disease drug development in the era of the NIA-AA Research Framework." Alzheimers Dement (2018). [DOI: 10.1016/j.jalz.2018.03.003]https://doi.org/10.1016/j.jalz.2018.03.003) PubMed: 29653605
[Khachaturian AS et al.. "New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia." Alzheimers Dement (2018). [DOI: 10.1016/j.jalz.2018.05.002]https://doi.org/10.1016/j.jalz.2018.05.002) PubMed: 29842864
[Rogers SL et al.. "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's Disease. Donepezil Study Group." Neurology (1998). DOI)
[Afshar S et al.. "Plasma proteomic associations with Alzheimer's Disease endophenotypes." Nature aging (2025). DOI)
[Aisen P et al.. "The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's Disease based on clearcut biomarker evidence." Alzheimers Dement (2025). DOI)
[Doody RS et al.. "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's Disease." The New England journal of medicine (2014). DOI)
[Fillenbaum GG, Mohs R. "CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting." Journal of Alzheimer's Disease : JAD (2023). DOI)
[Näslund J et al.. "Correlation between elevated levels of Amyloid-Beta-peptide in the brain and cognitive decline." JAMA (2000). DOI)
[Khachaturian AS et al.. "Future prospects and challenges for Alzheimer's Disease drug development in the era of the NIA-AA Research Framework." Alzheimers Dement (2018). DOI)
[Khachaturian AS et al.. "New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia." Alzheimers Dement (2018). DOI)
[Rogers SL et al.. "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's Disease. Donepezil Study Group." Neurology (1998). [DOI: 10.1212/wnl.50.1.136]https://doi.org/10.1212/wnl.50.1.136) PubMed: 9443470
[Afshar S et al.. "Plasma proteomic associations with Alzheimer's Disease endophenotypes." Nature aging (2025). [DOI: 10.1038/s43587-025-00965-4]https://doi.org/10.1038/s43587-025-00965-4) PubMed: 40931114
[Aisen P et al.. "The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's Disease based on clearcut biomarker evidence." Alzheimers Dement (2025). [DOI: 10.1002/alz.14342]https://doi.org/10.1002/alz.14342) PubMed: 39535341
[Doody RS et al.. "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's Disease." The New England journal of medicine (2014). [DOI: 10.1056/NEJMoa1312889]https://doi.org/10.1056/NEJMoa1312889) PubMed: 24450890
[Fillenbaum GG, Mohs R. "CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting." Journal of Alzheimer's Disease : JAD (2023). [DOI: 10.3233/JAD-230026]https://doi.org/10.3233/JAD-230026) PubMed: 36938738
[Näslund J et al.. "Correlation between elevated levels of Amyloid-Beta-peptide in the brain and cognitive decline." JAMA (2000). [DOI: 10.1001/jama.283.12.1571]https://doi.org/10.1001/jama.283.12.1571) PubMed: 10735393
[Khachaturian AS et al.. "Future prospects and challenges for Alzheimer's Disease drug development in the era of the NIA-AA Research Framework." Alzheimers Dement (2018). [DOI: 10.1016/j.jalz.2018.03.003]https://doi.org/10.1016/j.jalz.2018.03.003) PubMed: 29653605
[Khachaturian AS et al.. "New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia." Alzheimers Dement (2018). [DOI: 10.1016/j.jalz.2018.05.002]https://doi.org/10.1016/j.jalz.2018.05.002) PubMed: 29842864
[Rogers SL et al.. "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's Disease. Donepezil Study Group." Neurology (1998). DOI)
[Afshar S et al.. "Plasma proteomic associations with Alzheimer's Disease endophenotypes." Nature aging (2025). DOI)
[Aisen P et al.. "The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's Disease based on clearcut biomarker evidence." Alzheimers Dement (2025). DOI)
[Doody RS et al.. "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's Disease." The New England journal of medicine (2014). DOI)
[Fillenbaum GG, Mohs R. "CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting." Journal of Alzheimer's Disease : JAD (2023). DOI)
[Näslund J et al.. "Correlation between elevated levels of Amyloid-Beta-peptide in the brain and cognitive decline." JAMA (2000). DOI)
[Khachaturian AS et al.. "Future prospects and challenges for Alzheimer's Disease drug development in the era of the NIA-AA Research Framework." Alzheimers Dement (2018). DOI)
[Khachaturian AS et al.. "New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia." Alzheimers Dement (2018). DOI)
[Rogers SL et al.. "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's Disease. Donepezil Study Group." Neurology (1998). [DOI: 10.1212/wnl.50.1.136]https://doi.org/10.1212/wnl.50.1.136) PubMed: 9443470
[Afshar S et al.. "Plasma proteomic associations with Alzheimer's Disease endophenotypes." Nature aging (2025). [DOI: 10.1038/s43587-025-00965-4]https://doi.org/10.1038/s43587-025-00965-4) PubMed: 40931114
[Aisen P et al.. "The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's Disease based on clearcut biomarker evidence." Alzheimers Dement (2025). [DOI: 10.1002/alz.14342]https://doi.org/10.1002/alz.14342) PubMed: 39535341
[Doody RS et al.. "Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's Disease." The New England journal of medicine (2014). [DOI: 10.1056/NEJMoa1312889]https://doi.org/10.1056/NEJMoa1312889) PubMed: 24450890
[Fillenbaum GG, Mohs R. "CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting." Journal of Alzheimer's Disease : JAD (2023). [DOI: 10.3233/JAD-230026]https://doi.org/10.3233/JAD-230026) PubMed: 36938738
[Näslund J et al.. "Correlation between elevated levels of Amyloid-Beta-peptide in the brain and cognitive decline." JAMA (2000). [DOI: 10.1001/jama.283.12.1571]https://doi.org/10.1001/jama.283.12.1571) PubMed: 10735393
[Khachaturian AS et al.. "Future prospects and challenges for Alzheimer's Disease drug development in the era of the NIA-AA Research Framework." Alzheimers Dement (2018). [DOI: 10.1016/j.jalz.2018.03.003]https://doi.org/10.1016/j.jalz.2018.03.003) PubMed: 29653605
[Khachaturian AS et al.. "New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia." Alzheimers Dement (2018). [DOI: 10.1016/j.jalz.2018.05.002]https://doi.org/10.1016/j.jalz.2018.05.002) PubMed: 29842864
Recent work by [Richard C. Mohs[/researchers/[richard-mohs[/researchers/[richard-mohs[/researchers/[richard-mohs--TEMP--/researchers)--FIX-- focuses on clinical trial design, outcome measures, and drug development for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.
The study of Richard C. Mohs has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.